Originally, the initiative, led by the National Institute of General Medical Sciences and eight other NIH institutes, was funded from 2000 to 2005.
The following groups will receive funding:
- The Pharmacogenetics and Pharmacogenomics Knowledge Base, headed by Russ Altman at Standford University School of Medicine, will receive $13.7 million;
- Pharmacogenetics of Nicotine Addiction and Treatment, headed by Neal Benowitz at UCSF, will receive $10 million;
- The Consortium on Breast Cancer Pharmacogenomics, headed by David Flockhart at Indiana University School of Medicine, will receive $11.6 million;
- Pharmacogenetics of Membrane Transporters, headed by Kathleen Giacomini at UCSF, will receive $15 million;
- Pharmacogenomic Evaluation of Antihypertensive Responses, headed by Julie Johnson at the University of Florida, Gainesville, will receive $11.1 million;
- Pharmacogenetics and Risk of Cardiovascular Disease, headed by Ronald Krauss at UC Berkeley/Lawrence Berkeley National Laboratory, will receive $14.8 million;
- Functional Polymorphism Analysis in Drug Pathways, headed by Howard McLeod at Washington University, will receive $10.5 million;
- Pharmacogenetics of Anticancer Agents, headed by Mark Ratain at the University of Chicago and Mary Relling at St. Jude Children's Hospital, will receive $14.9 million;
- Pharmacogenomics of Arrhythmia Therapy, headed by Dan Roden at Vanderbilt University, will receive $14 million;
- The Amish Pharmacogenomics of Antiplatelet Intervention Study, headed by Alan Shuldiner at the University of Maryland School of Medicine, will receive $7.5 million;
- Pharmacogenetics of Phase II Drug Metabolizing Enzymes, headed by Richard Weinshilboum at the Mayo Clinic College of Medicine, will receive $12.6 million;
- Pharmacogenetics of Asthma Treatment, headed by Scott Weiss at Brigham and Women's Hospital and Harvard Medical School, will receive $16.8 million.